PANews reported on August 21st that according to an announcement on the SEC's official website, Nasdaq has decided to suspend trading of Windtree Therapeutics (WINT) common stock and initiate delisting procedures starting at the opening of trading on August 21, 2025, due to its failure to comply with Nasdaq Listing Rule 5550(a)(2). The company's stock will be transferred to the OTC market for trading under the symbol WINT. Windtree Therapeutics has applied for listing on the OTCID segment, but approval is not guaranteed. The company's business and operations remain unaffected, and it will continue to submit regular reports to the SEC.

As reported last month, publicly listed Windtree announced it had secured $520 million in new funding to expand its BNB funding strategy .